Show Notes

This Week In Wellness a pre-print study published by medRxiv for the first time measured the prevalence of COVID-19 antibodies in a representative sample of the Californian population. Stating that “to date, many epidemic projections and policies addressing COVID-19 have been designed without seroprevalence data to inform epidemic parameters”. “A sero-survey gives you a snapshot in time of who is infected in your given population,” says Kanta Subbarao, a virologist at the Peter Doherty Institute for Infection and Immunity in Melbourne going on to say that these kinds of studies are very important for a virus that can cause mild or no symptoms.